SZABO SCANDIC

Part of Europa Biosite

# Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

## Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

## Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand


**SZABO-SCANDIC HandelsgmbH**

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

# DAMGO

**Cat. No.:** HY-P0210

**CAS No.:** 78123-71-4

**Molecular Formula:** $C_{26}H_{35}N_5O_6$

**Molecular Weight:** 514

**Sequence:** Tyr-{d-Ala}-Gly-{Me-Phe}-Gly-ol

**Sequence Shortening:** Y-{d-Ala}-G-{Me-Phe}-G-ol

**Target:** Opioid Receptor

**Pathway:** GPCR/G Protein; Neuronal Signaling

**Storage:** Sealed storage, away from moisture and light
Powder -80°C 2 years
-20°C 1 year
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



## SOLVENT & SOLUBILITY

**In Vitro**

$H_2O$ : ≥ 100 mg/mL (194.55 mM)
DMSO : 33.33 mg/mL (64.84 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.

| Preparing Stock Solutions | Mass / Solvent / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 1.9455 mL | 9.7276 mL | 19.4553 mL |
| | 5 mM | 0.3891 mL | 1.9455 mL | 3.8911 mL |
| | 10 mM | 0.1946 mL | 0.9728 mL | 1.9455 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (4.86 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description** DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a $K_d$ of 3.46 nM for native μ-OPR[1].

| | |
|---|---|
| **$IC_{50}$ & Target** | μ Opioid Receptor/MOR |
| **In Vitro** | DAMGO (1-10 μM) significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival, but does not down-regulate CXCR4 protein expression[2].<br>DAMGO (1 μM) effectively inhibits the prostaglandin E 2 (PGE 2) induced increase in a tetrodotoxin-resistant voltage-gated $Na^+$ current (TTX-R $I_{Na}$), i.e. PGE 2 (1 μM) can increase the TTX-R $I_{Na}$ peak by 103 % compared to 24.9 % with the addition of DAMGO[3].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| **In Vivo** | DAMGO (i.v., 0.5-2 mg/kg) can produce significant anti-injury effects on injured paws of male Sprague-Dawley rats weighing 200-225 g in a dose-dependent manner, producing an effective and long-lasting analgesic effect[4].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## PROTOCOL

| | |
|---|---|
| **Cell Assay** [2] | Neurons (9 days in vitro) are treated with DAMGO (10 μM) for 24 h in their original culture dish, subsequently transferred to a dish containing $Mg^{2+}$-free saline with glycine (15 μM), and exposed to NMDA (100 μM) and/or CXCL12 (20 nM) in absence of glia. After treatments, neurons are moved back into the original culture dishes containing glia. Neuronal death is evaluated after 24 h. Hoechst 33342 (3 μg/mL) combined with cleaved caspase-3 (1:100) staining is used to identify normal and apoptotic cells[2].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

## CUSTOMER VALIDATION

- Cell. 2023 Jan 19;186(2):413-427.e17.
- Cell. 2022 Nov 10;185(23):4361-4375.e19.

See more customer validations on www.MedChemExpress.com

## REFERENCES


[1]. Gold MS, et al. DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro. Neurosci Lett. 1996 Jul 12;212(2):83-6.

[2]. Desmeules JA, et al. Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain. Pain. 1993 Jun;53(3):277-285.

[3]. FEBS Lett. 1995 Jan 2;357(1):93-7. Onogi T, et al. DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops.

[4]. Patel JP, et al. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol. 2006 Dec;12(6):492-500.





Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA